Measuring the apparent diffusion coefficient in primary rectal tumors: is there a benefit in performing histogram analyses? by unknown
Measuring the apparent diffusion coefficient
in primary rectal tumors: is there a benefit
in performing histogram analyses?
Miriam M. van Heeswijk,1,2,3 Doenja M. J. Lambregts,1 Monique Maas,1,3
Max J. Lahaye,1 Z. Ayas,3 Jos M. G. M. Slenter,3 Geerard L. Beets,2,4
Frans C. H. Bakers,3 Regina G. H. Beets-Tan1,2
1Department of Radiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE Amsterdam, The Netherlands
2GROW School for Oncology and Developmental Biology- Maastricht University, Universiteitssingel 40, 6229 ER Maastricht,
The Netherlands
3Department of Radiology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
4Department of Surgery, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE Amsterdam, The Netherlands
Abstract
Purpose: The apparent diffusion coefficient (ADC) is a
potential prognostic imaging marker in rectal cancer.
Typically, mean ADC values are used, derived from
precise manual whole-volume tumor delineations by
experts. The aim was first to explore whether non-precise
circular delineation combined with histogram analysis
can be a less cumbersome alternative to acquire similar
ADC measurements and second to explore whether
histogram analyses provide additional prognostic infor-
mation.
Methods: Thirty-seven patients who underwent a pri-
mary staging MRI including diffusion-weighted imaging
(DWI; b0, 25, 50, 100, 500, 1000; 1.5 T) were included.
Volumes-of-interest (VOIs) were drawn on b1000-DWI:
(a) precise delineation, manually tracing tumor bound-
aries (2 expert readers), and (b) non-precise delineation,
drawing circular VOIs with a wide margin around the
tumor (2 non-experts). Mean ADC and histogram
metrics (mean, min, max, median, SD, skewness, kurto-
sis, 5th–95th percentiles) were derived from the VOIs and
delineation time was recorded. Measurements were
compared between the two methods and correlated with
prognostic outcome parameters.
Results: Median delineation time reduced from 47–165 s
(precise) to 21–43 s (non-precise). The 45th percentile of
the non-precise delineation showed the best correlation
with the mean ADC from the precise delineation as the
reference standard (ICC 0.71–0.75). None of the mean
ADC or histogram parameters showed significant prog-
nostic value; only the total tumor volume (VOI) was
significantly larger in patients with positive clinical N
stage and mesorectal fascia involvement.
Conclusion: When performing non-precise tumor delin-
eation, histogram analysis (in specific 45th ADC per-
centile) may be used as an alternative to obtain similar
ADC values as with precise whole tumor delineation.
Histogram analyses are not beneficial to obtain addi-
tional prognostic information.
Key words: Rectal cancer—Apparent diffusion
coefﬁcient—Histogram analysis—Prognostic marker
In recent years, diffusion-weighted imaging (DWI) has
increasingly found its way to the clinical practice of
magnetic resonance (MR) imaging in rectal cancer. Its
value has particularly been demonstrated in the restaging
setting to assess the response of the primary tumor to
neoadjuvant chemoradiotherapy (CRT) and determine
whether or not a residual tumor mass is still present
within the post-radiation ﬁbrosis [1–3]. In this setting, the
addition of DWI has been shown to improve the sensi-
tivity for tumor restaging after CRT by >30% in a re-
cent meta-analysis [4].
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Furthermore, in research settings, several studies have
shown that quantifying the diffusion of rectal tumors by
measuring the apparent diffusion coefﬁcient (ADC) may
be used as an imaging biomarker. This could be beneﬁ-
cial in clinics to predict prognostic factors such as nodal
stage, mesorectal fascia (MRF) involvement, and histo-
logical differentiation grade [5–8]. Moreover, ADC may
have value to predict therapeutic response [9–13], which
(in the future) could impact treatment stratification. For
example, neoadjuvant treatment may be further tailored
depending on the anticipated treatment response.
Moreover, accurate response evaluation can benefit the
selection of good responding patient who can be candi-
dates for minimally invasive follow-up treatments such
as local excision or watchful waiting.
ADC values are most often expressed as the mean
ADC, which can be acquired either from a single tumor
slice [14, 15], from tumor sample measurements [3, 5], or
by manually delineating the whole tumor volume on the
diffusion-weighted images [1, 12, 16, 17]. The latter ap-
proach is most commonly advocated and has been shown
to provide the most reproducible results [18, 19]. As such,
it is now considered more or less the standard reference
method of choice to acquire tumor ADC measurements.
It is, however, a labor-intensive and time-consuming
method, which is one of the factors that hamper the
translation of the use of quantitative ADC measures
from research settings to clinical practice.
Hypothetically, an alternative approach to obtain
whole-volume ADC measurements could be to perform a
non-precise tumor delineation, e.g., by roughly placing a
circular volume of interest (VOI) with a wide margin
around the tumor. This saves time, but non-tumoral
tissues such as mesorectal fat, normal bowel wall and
lumen, and the surrounding organs and muscle struc-
tures will be included in the VOIs, which will affect the
ADC measurements. In theory, this effect may be com-
pensated for by adding histogram analyses as a post-
processing step. With histogram analysis, we analyze the
spectrum of ADC values obtained from all voxels within
the VOI. By doing so, we can not only extract the mean
ADC values, but also, for example, calculate the mini-
mum and maximum values and different percentile ran-
ges. In principle, this information may be used to
speciﬁcally focus on those ADC values within the VOI
representing tumor (which will typically be the lower
ADC values within the spectrum), for example by
extracting only lower percentile values, thereby ﬁltering
out ‘noise’ from other included tissues. This could allow
radiologist to save time with the delineation process
whilst in principle obtaining the same ADC information.
In addition, adding histogram analysis provides infor-
mation about the distribution of ADC values within the
tumor, which can potentially offer valuable additional
insights into tumor structure and heterogeneity. This
information could be of added beneﬁt to predict response
and prognosis, as has been suggested by previous authors
[9, 10].
Therefore, the aim of this study was twofold. The
primary aim was to test—on primary staging (pre-treat-
ment) DWI-MRI—if histogram ADC analysis can be
used to compensate non-precise tumor delineation and
may be used as an alternative method to acquire similar
ADC values as would normally be derived from precise
whole-volume tumor delineation as the current ‘standard
of reference.’ The secondary aim was to evaluate if his-
togram analysis provides valuable additional informa-
tion to predict treatment outcome and prognosis.
Materials and methods
Patients
Forty-four patients diagnosed with and treated for rectal
cancer at Maastricht University Medical Centre between
October 2012 and June 2014 were considered for inclu-
sion in this retrospective study. The study was approved
by the local ethical institutional review board. Due to the
retrospective nature of the study, informed consent was
waived. Inclusion criteria were (a) biopsy-proven non-
mucinous type rectal adenocarcinoma, (b) availability of
a primary staging MRI including DWI (with a stan-
dardized acquisition protocol at 1.5 T), and (c) avail-
ability of follow-up data on treatment and outcome.
Seven patients were excluded for the following reasons:
severe artifacts on DWI, e.g., susceptibility artifacts due
to air or metal prostheses (n = 5), multiple tumor sites in
the rectum (n = 1), and prior pelvic radiation in
(n = 1). This left a final study population of 37 patients.
MR Imaging
All patients underwent a primary staging MRI at 1.5T
MRI (Ingenia system, Philips Medical Systems, Best, The
Netherlands), using a phased-array 16-channel body coil.
The patients did not receive any bowel preparation. An
intravenous bolus injection of 20 mg of butylscopo-
lamine (Buscopan, Boehringer Ingelheim bv, Ingelheim,
Germany) was administered intravenously to reduce
peristaltic movement. The standard imaging protocol
included standard two-dimensional T2-weighted (T2 W)
fast spin-echo sequences in 3 orthogonal directions (with
the transverse images angled perpendicular and the
coronal images angled parallel to the tumor axis as
identified on the sagittal scan), and an axial echo planar
imaging (EPI) DWI sequence angled in the same plane as
the T2W transverse images. The DWI sequence was
performed with spectral attenuated inversion recovery
(SPAIR) fat suppression (b values 0, 25, 50, 100, 500,
1000 s/mm2; TR/TE 4147/66 ms; EPI factor 77; 5 num-
ber of signals acquired; 1.82 9 2.26 9 5.00 mm acquisi-
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tion voxel size, 20 slices, slice gap of 0.5 mm; acquisition
time of 6:44 min). Apparent diffusion coefficient maps
were automatically generated by the operating system,
using a mono-exponential decay model including all six
b values.
Precise and non-precise tumor delineation
All primary staging MR images were transferred to an
ofﬂine workstation for tumor delineation, which was
performed using the freely available program MedView
(Github clmedview, Maastricht, the Netherlands). Vol-
umes-of-interest (VOIs) were drawn on the high-b-value
(b1000) diffusion images in two ways: (a) precise delin-
eation and (b) non-precise delineation. For the precise
delineation, two experienced radiologists (R1 and R2;
both with 8 years of experience in reading rectal MRI)
manually closely traced the tumor boundaries on each
consecutive slice to include the whole tumor volume. For
the non-precise delineation, two additional non-expert
Fig. 1. Example of the MR exam of an 82-year-old female
patient. A Axial T2W image shows a semi-circular tumor,
B the b-1000 DWI shows high signal in the tumor area,
C example of the precise delineation (solid line performed by
reader 1) and the non-precise delineation (dotted line per-
formed by reader 3), the latter including both tumor and sur-
rounding tissues, and D both delineations transferred to the
ADC map.
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resident-level readers (R3 and R4; both with no specific
previous experience in reading rectal MRI) drew a cir-
cular/oval VOI with a margin around the tumor on each
slice. The T2W images were at the disposal of all four
readers for anatomical reference. An example illustrating
the two delineation methods is shown in Fig. 1. The time
required to perform the delineations was recorded in a
representative sample of n = 18 study patients (for 1
expert and 1 non-expert reader) in order to quantify the
potential reduction in measurement time.
Histogram metrics
VOIs were transferred from the b1000 diffusion images
to the ADC map to calculate mean ADCs and histogram
metrics. Histogram plots were generated using a dedi-
cated script written in MATLAB (The MathWorks Inc.,
Natick, MA, 2000) by one of the authors (JMGMS). The
following histogram parameters were calculated: mini-
mum, maximum, mean, median (50th percentile), stan-
dard deviation (SD), skewness, kurtosis, and every ﬁfth
percentile (5th–95th). The total volume (cm3) of each
VOI was also recorded.
Outcome parameters
Various prognostic and therapeutic outcome parameters
were collected: (a) from the primary staging MRI re-
ports, the cT stage, cN stage, and mesorectal fascia
(MRF) involvement; (b) from the clinical patient data-
base, the presence of distant metastases, neoadjuvant,
and surgical procedures; (c) from the pathology reports
(of the biopsy and surgical specimens), the tumor dif-
ferentiation grade; and (d) in patients undergoing a long
course of neoadjuvant treatment, the ﬁnal treatment re-
sponse deﬁned as the tumor regression grade (TRG;
method of Mandard) assessed at histopathology after
surgery, where TRG 1–2 was considered a good response
and TRG 3–5 a poor response [20].
Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS, version 23.0, Inc.,
Chicago, IL). The intraclass correlation coefﬁcient (ICC;
using a two-way mixed method with absolute agreement
for single measures) was used to calculate the agreement
between the different readers and delineation methods.
ICCs were also used to compare the various ADC his-
togram metrics of the non-precise delineation to the
mean ADC of the precise delineation (being the most
commonly used parameter in previous literature and
therefore serving as the ‘standard of reference’). Agree-
ment was additionally assessed using Bland–Altman
statistics. Independent sample T tests (or Mann–Whitney
U/Wilcoxon Rank test in case of non-normally dis-
tributed data) were used to compare the mean ADC
values and various histogram metrics between (1) cN0 vs.
Table 1. Mean volumes, ADCs, and histogram metrics including interobserver agreement between the readers and between the delineation methods
Precise delineation Non-precise delineation Precise vs. non-precise
Reader 1 Reader 2 ICC Reader 3 Reader 4 ICC R1 + R2a R3 + R4a ICC
Volume 3218 2858 0.91 8653 9629 0.88 3038 9141 0.49
Mean 1.44 1.43 0.98 1.51 1.51 0.96 1.43 1.51 0.64
Minimum 0.31 0.32 0.78 0.01 0.01 0.80 0.31 0.01 0.00
Maximum 3.18 3.18 0.82 3.58 3.61 0.95 3.18 3.60 0.64
SD 0.40 0.40 0.92 0.57 0.58 0.93 0.40 0.57 0.35
Skewness 0.66 0.67 0.87 0.15 0.17 0.83 0.67 0.16 0.12
Kurtosis 4.28 4.27 0.80 3.42 3.36 0.73 4.28 3.39 0.31
5th 0.89 0.88 0.93 0.58 0.57 0.90 0.88 0.57 0.20
10th 1.00 0.98 0.94 0.79 0.78 0.91 0.99 0.78 0.26
15th 1.07 1.05 0.96 0.94 0.92 0.90 1.06 0.93 0.35
20th 1.13 1.11 0.97 1.05 1.03 0.89 1.12 1.04 0.46
25th 1.18 1.16 0.98 1.14 1.12 0.90 1.17 1.13 0.57
30th 1.23 1.21 0.98 1.22 1.21 0.92 1.22 1.22 0.64
35th 1.28 1.25 0.98 1.30 1.29 0.93 1.27 1.29 0.67
40th 1.32 1.30 0.98 1.37 1.36 0.94 1.35 1.36 0.67
45% 1.37 1.34 0.98 1.44 1.43 0.94 1.36 1.43 0.67
50% (median) 1.40 1.38 0.98 1.50 1.50 0.95 1.39 1.50 0.65
55th 1.46 1.44 0.98 1.57 1.57 0.95 1.45 1.57 0.64
60th 1.51 1.49 0.98 1.64 1.64 0.96 1.50 1.64 0.63
65th 1.56 1.54 0.98 1.71 1.71 0.96 1.55 1.71 0.62
70th 1.62 1.60 0.98 1.79 1.79 0.96 1.61 1.79 0.62
75th 1.69 1.67 0.98 1.87 1.88 0.96 1.68 1.88 0.60
80th 1.76 1.75 0.98 1.97 1.98 0.97 1.75 1.98 0.58
85th 1.85 1.84 0.97 2.09 2.10 0.97 1.84 2.09 0.56
90th 1.96 1.96 0.96 2.24 2.25 0.97 1.96 2.25 0.53
95th 2.15 2.15 0.95 2.46 2.50 0.94 2.15 2.48 0.52
a Results are averaged between R1 + R2 and R3 + R4, respectively
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cN+ patients, (2) cMRF- vs. cMRF+ patients, (3)
patients with vs. without metastases, (4) tumors with
good–moderate vs. poor differentiation grade at
histopathology, and (5) good (TRG 1–2) vs. poor (TRG
3–5) responders. The Holm–Bonferroni correction
method was applied to correct for multiple testing [21].
A Wilcoxon Rank test was performed to compare the
delineation time between the two methods. P values
£0.05 were considered statistically significant.
Results
Patient and treatment characteristics
Of the 37 study patients, 28 were male and nine female.
Median age was 72 (range 29–86). Initial tumor stage on
MRI was cT1–2 in 7 patients, cT3 in 27 patients, and cT4
in 3 patients. Eleven patients were cN0 and 26 were
cN+. Eight patients had distant metastasis. Fifteen pa-
tients with non-locally advanced tumors underwent sur-
gery without neoadjuvant treatment or immediately after
a short course of 5 9 5 Gy. Seventeen locally advanced
patients underwent a long course of CRT (28 9 1.8 Gy
radiotherapy with 2 9 825 mg/m2/d capecitabine) or
5 9 5 Gy with a prolonged waiting interval before sur-
gery. Five patients received palliative care.
Precise vs. non-precise delineation method
VOIs, mean ADCs, and histogram metrics derived from
the primary staging MRIs are provided in Table 1. The
mean volume of the VOIs used to calculate the ADCs
was 3.22 cm3 (R1) and 2.86 cm3 (R2) for the precise
delineation method vs. 8.65 cm3 (R3) and 9.63 cm3 (R4)
for the non-precise delineation method (P < 0.001).
Mean ADC (910-3 mm2/s) was 1.44 (R1) and 1.43 (R2)
for the precise delineation vs. 1.51 (R3) and 1.51 (R4) for
the non-precise delineation (P = 0.01–0.06). An exam-
ple comparing the histograms of the precise and non-
precise delineation methods is shown in Fig. 2. Table 2
shows the delineation times for the two measurement
methods. Compared to precise delineation, non-precise
delineation significantly reduced the delineation time for
small, intermediate-sized as well as for the large tumors
with a median reduction in measurement time of 28 up to
123 s per patient/tumor.
Interobserver and intermethod agreement
ICCs between the different readers and delineation
methods are given in Table 1. Interobserver agreement
was excellent, both for the precise method (R1 vs. R2)
and the non-precise method (R3 vs. R4) with ICCs
ranging between 0.80 and 0.98. ICCs comparing the
precise and non-precise methods were poor to good (ICC
0.00–0.67). Table 3 shows the correlations of the various
histogram metrics of the non-precise method to the mean
ADC of the precise method (as the standard of refer-
ence): best correlation was found for the 45th percentile
ADC of the non-precise method (ICC of 0.71–0.75).
Results for the mean ADC and 45th percentile mea-
surements are illustrated using Bland–Altman plots in
Fig. 3.
Table 2. Delineation times for the non-precise and precise delineation methods
Tumor volume (cm3) Delineation time (s)
Precise Non-precise Difference P
Small (n = 6) 0.57 (0.16–1.05) 47 (29–65) 21 (15–25) 28 (14–40) 0.03
Intermediate (n = 6) 2.28 (1.87–2.49) 101 (77–145) 31 (30–37) 71 (40–109) 0.03
Large (n = 6) 6.24 (4.99–18.32) 165 (107–292) 43 (34–64) 123 (68–228) 0.03
NB, numbers are medians with ranges provided in parentheses
Delineation time was measured for reader 1 (precise) and reader 3 (non-precise) in a representative sample of n = 18 tumors that were categorized
into ‘small,’ ‘intermediate,’ and ‘large’ tumors by sorting all n = 37 tumors ascendingly according to their volume (derived from Table 1), dividing
the group into 3 equal subsets based on tumor volume and randomly selecting a sample of n = 6 from each group
Fig. 2. Example of the normalized histograms for the pre-
cise and non-precise delineation in the same patient. The
vertical lines in bold represent the mean ADC per method
(solid line indicating a mean ADC of 1.13 9 10-3 mm2/s for
the precise delineation and the dotted line indicating a mean
ADC of 1.64 9 10-3 mm2/s for the non-precise delineation).
These normalized histograms show that the ADC values of
the non-precise delineation are much more spread out due to
the inclusion of other tissues, resulting in a higher mean ADC.
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ADC histogram analysis vs. prognostic factors
In Table 4, VOIs, mean ADCs, and various histogram
metrics are compared between different prognostic and
response subgroups for both delineation methods. VOIs
were significantly larger in the cN+ patients (both for
the precise and non-precise delineation; P = 0.04) and in
patients with MRF involvement on MRI (for the precise
delineation; P = 0.04). Mean ADCs and the various
histogram metrics were not significantly different be-
tween these subgroups. For the other outcome parame-
ters (good vs. poor histopathological differentiation
grade, good vs. poor response, metastasized vs. non-
metastasized patients), none of the volume, ADC, or
histogram metrics resulted in any significant differences
between subgroups.
Discussion
The primary aim of this study was to assess the feasibility
of calculating ADC values of rectal tumors at the time of
primary staging using non-precise rectal tumor delin-
eation combined with histogram analysis as an alterna-
tive to precise manual tumor delineation, aiming to
simplify and speed up the delineation process. Precise
volumetric delineation (typically performed by manual
tracing of the tumor boundaries by expert readers) is the
most commonly used method in current literature to
calculate mean tumor ADCs and therefore in a way
considered the current ‘standard of reference’ method.
The beneﬁt of a non-precise delineation (e.g., simply
placing a circular ROI with a margin around the tumor
area) is that it is faster and can be performed by non-
experienced readers. The main drawback, however, is
that tissues other than tumor such as the normal rectal
wall, perirectal fat, and adjacent organs will be included
Table 3. ICCs constructed to explore which histogram parameter de-
rived from non-precise delineation correlates best with the mean ADC
of the precise delineation (as the standard of reference)




Non-precise R3 R4 R3 R4
Mean 0.63 0.63 0.63 0.62
Min 0.00 0.00 0.01 0.00
5th 0.02 0.01 0.02 0.01
10th 0.05 0.04 0.05 0.05
15th 0.09 0.09 0.09 0.09
20th 0.16 0.16 0.17 0.16
25th 0.27 0.26 0.28 0.26
30th 0.41 0.40 0.42 0.41
35th 0.55 0.55 0.56 0.55
40th 0.67 0.67 0.66 0.67
45th 0.73 0.75 0.71 0.73
50th (median) 0.72 0.74 0.71 0.72
55th 0.65 0.67 0.62 0.65
60th 0.55 0.58 0.53 0.55
65th 0.45 0.48 0.44 0.46
70th 0.36 0.38 0.36 0.37
75th 0.28 0.29 0.29 0.29
80th 0.22 0.22 0.22 0.23
85th 0.16 0.16 0.17 0.17
90th 0.11 0.11 0.12 0.12
95th 0.08 0.07 0.08 0.08
Max 0.02 0.02 0.02 0.02
NB, best results are printed in bold
Fig. 3. Bland–Altman plots showing the reproducibility for
tumor ADC measurements plotted as the mean ADC of the
two methods (x-axis) against the difference in ADC between
the two methods (y-axis). The middle line represents the
mean absolute difference (bias) between the two methods,
while the outer lines represent the 95% confidence intervals
(limits of agreement). Plot A compares the mean ADC derived
from the precise delineation and non-precise delineation. Plot
B compares the mean of the precise method and the 45th
percentile of the non-precise method. Measurements were
averaged for the two readers for both methods.
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in the delineation, which will affect the mean ADC. Our
hypothesis was that this effect may be overcome by
adding histogram analysis to ﬁlter out these effects and
speciﬁcally focus on ADC values of the tumor within the
histogram in order to acquire similar ADCs as would
have normally been derived by calculating the mean
ADC from a precise delineation.
Our results show that when using histogram post-
processing in such a way, the 45th percentile ADC from
the non-precise delineation showed the best correlation
with the mean ADC from the precise delineation as the
standard of reference (ICC 0.71–0.75). Results without
the addition of histogram post-processing were consid-
erably poorer with an ICC of only 0.64 between the
mean ADCs of the precise and non-precise methods.
The main reason for this poorer correlation is that the
non-precise delineation resulted in remarkably higher
overall ADC values, which can be explained by the fact
that voxels with relatively high ADCs, for example,
from the bladder, seminal vesicles, prostate, and normal
rectal wall were often included in the VOIs (see Figs. 1
and 2).
Although the use of the 45th percentile instead of
mean ADC from the non-precise delineation thus im-
proved the results, an agreement with a maximum ICC of
0.75 was still suboptimal, especially when comparing it,
for example, to the ICC of 0.98 between the two readers
for the precise delineation method. A previous study
explored the use of (semi-)automated tumor segmenta-
tion (using computer algorithms) as an alternative
method to overcome the problem of time-consuming and
labor-intensive manual tumor segmentation in rectal
cancer. Similar to the current study, the results of manual
delineation were used as the reference standard. Al-
though the main outcome was the VOI itself (and not the
ADC as in our study), high ICCs of 0.91–0.97 for semi-
automated tumor segmentation were reported [22]. It
would seem logical to assume that such an approach
(given the excellent agreement when comparing the
VOIs) would also result in a good agreement in ADC
measurements if these were to be derived from these
(semi-)automatically generated VOIs. It was reported
that the median delineation time decreased from
180–296 s for precise manual delineation to 41–69 s for
semi-automated segmentation, which entails a consider-
able decrease in time and input required from readers
[22]. In our study, delineation time also significantly re-
duced with the non-precise method to a median mea-
surement time ranging between 21 and 43 s per
tumor/patient depending on the tumor volume. This
would make it a similarly or even more effective solution
with regard to time efficacy with the added benefit that
the non-precise delineations can be performed by non-
experienced readers and do not necessarily require expert
input. The clinically relevant question is, however, if and
how different delineation methods affect the utility of the
acquired ADC measurements as a prognostic imaging
biomarker.
Therefore, the second aim of this study was to explore
the prognostic value of ADC measurements derived from
the two delineation methods. In addition, we aimed to
evaluate whether the addition of histogram analysis
provides valuable extra information. Previous studies
have shown that mean ADC at primary staging may
differentiate prognostically unfavorable tumor subtypes
(e.g., tumors with MRF involvement, clinical N+ stage,
tumor deposits, and poor differentiation grade) [5, 6]. In
our study, we could unfortunately not reproduce these
findings. Mean ADC values were not useful to differ-
entiate between cMRF- and cMRF+ tumors, cN- and
cN+ tumors, well and poorly differentiated histological
tumor subtypes, or between patients with/without
metastasized disease. Moreover, the addition of his-
togram parameters did not lead to improved results. For
the prediction of treatment response in the subgroup of
patients undergoing chemoradiotherapy, neither mean
ADC nor any of the histogram parameters showed sig-
nificant results to differentiate between the poor and
good responders using the tumor regression grade at
histopathology as the outcome. Results in the literature
regarding this issue have also been conflicting. Some
groups reported significantly lower mean ADC values in
patients who showed a good response to treatment,
suggesting that pre-treatment ADC may have potential
to predict response, which could be of potential clinical
benefit to tailor (neoadjuvant) treatment strategies
depending on the anticipated response [11–13, 23–25].
Conversely, other groups found—similar to the current
study—no significant differences in pre-treatment ADC
between responders and non-responders [25–29]. To
date, only a few studies have investigated the potential
benefit of adding histogram post-processing to predict
rectal tumor response. Nougaret et al. reported that
histogram metrics did not add to median ADC values for
the assessment of rectal tumor response after CRT [19].
Choi et al. found some promising results after CRT, with
significant differences between poor and good respon-
ders after CRT for several histogram parameters (mini-
mum ADC, 10th, 25th, 50th, and 75th percentiles) [10].
This was confirmed in another study by Cho et al. who
reported significantly different 10th and 25th percentile
values between responders and non-responders with
better diagnostic performance compared to mean ADC
[9]. However, similar to the findings of our current study,
Choi et al. find no benefit in any of the ADC or his-
togram metrics for pre-treatment prediction of response
[10].
Interestingly, the VOI was the only parameter that
resulted in signiﬁcant differences between some of the
favorable and unfavorable (cN+, cMRF+) subgroups.
Previous studies also showed superior results for DWI
tumor volumetry compared to ADC measurements, al-
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beit these studies focused on the assessment of tumor
response after chemoradiotherapy rather than for pre-
dicting prognostic factors at primary staging. Pre-treat-
ment DWI tumor volumes in those previous reports did
not show any signiﬁcant correlations with the ﬁnal
treatment outcome [1, 30], which is in line with our
current findings.
Our study had some limitations, the ﬁrst of which
being its retrospective nature and the relatively small
number of patients. Second, for some of the study pa-
tients not all of the outcome variables were available (for
example, because patients underwent palliative treatment
and did not proceed to surgery). Moreover, the prog-
nostic outcome factors (such as N stage and MRF
involvement) were primarily based on the MRI staging
result rather than histopathology. This method—also
previously used by other authors [5, 6]—was chosen,
since part of the study patients underwent neoadjuvant
treatment before surgery and in these patients the final
histopathology will no longer reflect the primary tumor
stage. We, however, acknowledge that the clinical staging
is a subjective measure that will be influenced by known
limitations of MRI in assessing these factors, as well as
radiologists’ experience. Third, mean ADC derived from
a precise expert delineation was arbitrarily defined as a
standard of reference, because it is the measure that is
currently most widely used in published reports. We
acknowledge, however, that this is a subjective standard
of reference that will vary, for example, depending on the
DWI image protocol (e.g., acquisition parameters, pa-
tient preparation, etc.) as well as the experience of the
readers. Finally, we performed our analyses based on the
assumption that the ADC values from both the precise
and non-precise methods are normally distributed within
patients (as illustrated in Fig. 2), which would make it
acceptable to identify the non-precisely measured 45th
percentile as the best surrogate measurement for the
mean ADC from the precise method. This was, however,
not tested for each individual patient.
In conclusion, the 45th percentile ADC of the his-
togram derived from non-precise delineation correlates
well with the mean ADC of the precise method and may
thus be used as an alternative measure. In our study, we
could not conﬁrm the previously reported potential value
of ADC measurements to predict the prognostic tumor
proﬁle or response to treatment. Moreover, histogram
ADC analysis did not appear to provide any additional
prognostic information. Tumor volume was the only
parameter found to correlate with prognostic features
(N+ and MRF+ status).
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